Prevalence of antigens and antibodies against SARS-CoV-2 in people deprived of liberty
Authors:
- Liana Osório FernandesLFLiana Osório Fernandes
- José Cláudio Garcia Lira NetoJosé Cláudio Garcia Lira Neto
- Marcela Helena Gambim FonsecaMFMarcela Helena Gambim Fonseca
- Jardeliny Corrêa da PenhaJPJardeliny Corrêa da Penha
- Alberto Pereira MadeiroAMAlberto Pereira Madeiro
- Malvina Thaís Pacheco RodriguesMRMalvina Thaís Pacheco Rodrigues
- Ariel de Sousa MeloAMAriel de Sousa Melo
- Márcio Dênis Medeiros MascarenhasMMMárcio Dênis Medeiros Mascarenhas
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (10)
Abstract
Aiming to estimate the prevalence of anti-SARS-CoV-2 antigens and antibodies among incarcerated individuals, an institution-based serological survey was conducted in seven prison units across four municipalities in the state of Piauí, Brazil, from April to October 2022. A probabilistic cluster sampling method was adopted. Interviews, rapid tests, and serological assays were performed to detect anti-SARS-CoV-2 antigens and antibodies. Prevalence rates, statistical associations using the chi-square test, and prevalence ratios through Poisson regression were calculated. Among the 848 participants, antigen prevalence was 1.1%. The prevalence of anti-SARS-CoV-2 antibodies ranged from 6.5% (IgM-S) to 98.9% (IgG-S). No significant differences were observed in antigen prevalence. The prevalence of IgG-N and IgG-S antibodies was higher among inmates in Teresina (PR=1.41; 95%CI: 1.08-1.46; PR=1.03; 95%CI: 1.01-1.05). Receiving at least two doses of a COVID-19 vaccine increased antibody seropositivity (IgM-S PR=2.08; 95%CI: 1.01-4.29; IgG-N PR=1.26; 95%CI: 1.08-1.46; IgG-S PR=1.02; 95%CI: 1.01-1.04). These findings reinforce the positive impact of vaccination and other control measures implemented in the incarcerated population during the COVID-19 pandemic.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Piauí
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 17 references indexed in Scilit:
- The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysisPathogens and Global Health, 2022
- Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infectionInternational Journal of Infectious Diseases, 2021
- Social inequalities and COVID-19 mortality in the city of São Paulo, BrazilInternational Journal of Epidemiology, 2021
- Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onsetProceedings of the National Academy of Sciences, 2021
- Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infectioneClinicalMedicine, 2021
- Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in MaranhãoRevista de Saúde Pública, 2020
- Mass Testing for SARS-CoV-2 in 16 Prisons and Jails — Six Jurisdictions, United States, April–May 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineCellular & Molecular Immunology, 2020
- EpiCollect: Linking Smartphones to Web Applications for Epidemiology, Ecology and Community Data CollectionPLOS ONE, 2009